Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Coave Therapeutics Closes €33 million…

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of…

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir and Mithra announce manufacturing…

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

eTheRNA immunotherapies and Ghent University…

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir’s COVID-19 antibody candidate neutralizes…

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. Announces FDA Clearance…

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

eTheRNA immunotherapies and Quantoom Biosciences…

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

eTheRNA and VUB expand strategic…

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

Novadip Biosciences reports positive data…

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics Establishes Medical Advisory…